Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(4.04)
# 1,707
Out of 5,044 analysts
116
Total ratings
35.7%
Success rate
11.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Maintained: Buy | n/a | $9.37 | - | 2 | Sep 18, 2026 | |
| IVA Inventiva | Initiated Coverage: Buy | n/a | $3.75 | - | 1 | Jul 17, 2026 | |
| SLN Silence Therapeutics | Initiated Coverage: Buy | n/a | $12.70 | - | 1 | Jun 24, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $101 | $35.10 | +187.75% | 10 | Jun 7, 2026 | |
| STTK Shattuck Labs | Initiated Coverage: Buy | n/a | $5.85 | - | 1 | Apr 27, 2026 | |
| MANE Veradermics | Initiated Coverage: Buy | n/a | $108.68 | - | 1 | Mar 1, 2026 | |
| TVTX Travere Therapeutics | Reiterated: Buy | n/a | $64.74 | - | 7 | Feb 20, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterated: Buy | n/a | $12.35 | - | 9 | Dec 4, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | n/a | $534.40 | - | 4 | Nov 4, 2025 | |
| ACRS Aclaris Therapeutics | Reiterated: Buy | n/a | $5.40 | - | 2 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.88 | n/a | 6 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.3765 | n/a | 10 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $16.69 | n/a | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.38 | n/a | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $39.98 | n/a | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $67.74 | n/a | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $56.47 | n/a | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.36 | n/a | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $2.8 | $1.89 | n/a | 10 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.17 | n/a | 2 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 → $3.5 | $1.60 | n/a | 3 | Jan 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $23 | $5.28 | n/a | 8 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 → $62 | $7.75 | n/a | 8 | Oct 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $26.46 | n/a | 8 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $1.40 | n/a | 8 | Aug 5, 2021 |
Evommune
Sep 18, 2026
Maintained: Buy
Price Target: n/a
Current: $9.37
Upside: -
Inventiva
Jul 17, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $3.75
Upside: -
Silence Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $12.70
Upside: -
Structure Therapeutics
Jun 7, 2026
Reiterated: Buy
Price Target: $101
Current: $35.10
Upside: +187.75%
Shattuck Labs
Apr 27, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $5.85
Upside: -
Veradermics
Mar 1, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $108.68
Upside: -
Travere Therapeutics
Feb 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $64.74
Upside: -
MoonLake Immunotherapeutics
Dec 4, 2025
Reiterated: Buy
Price Target: n/a
Current: $12.35
Upside: -
Madrigal Pharmaceuticals
Nov 4, 2025
Upgraded: Buy
Price Target: n/a
Current: $534.40
Upside: -
Aclaris Therapeutics
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.40
Upside: -
Sep 26, 2025
Reiterated: Buy
Price Target: n/a
Current: $12.88
Upside: n/a
Sep 15, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.3765
Upside: n/a
Aug 15, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $16.69
Upside: n/a
Jul 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.38
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $39.98
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $67.74
Upside: n/a
Mar 3, 2025
Reiterated: Buy
Price Target: n/a
Current: $56.47
Upside: n/a
Jan 21, 2025
Downgraded: Hold
Price Target: n/a
Current: $11.36
Upside: n/a
Aug 11, 2023
Reiterated: Buy
Price Target: $14 → $2.8
Current: $1.89
Upside: n/a
Mar 17, 2023
Rated: Hold
Price Target: n/a
Current: $5.17
Upside: n/a
Jan 10, 2023
Reiterated: Buy
Price Target: $5 → $3.5
Current: $1.60
Upside: n/a
Sep 12, 2022
Reiterated: Buy
Price Target: $27 → $23
Current: $5.28
Upside: n/a
Oct 18, 2021
Reiterated: Buy
Price Target: $58 → $62
Current: $7.75
Upside: n/a
Sep 21, 2021
Reiterated: Buy
Price Target: $44
Current: $26.46
Upside: n/a
Aug 5, 2021
Reiterated: Buy
Price Target: $22
Current: $1.40
Upside: n/a